Apnimed (NASDAQ:APMD) Research Coverage Started at Bank of America

Bank of America started coverage on shares of Apnimed (NASDAQ:APMD) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $41.00 target price on the stock.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald began coverage on shares of Apnimed in a research note on Tuesday. They set an “overweight” rating and a $60.00 price target on the stock. Wall Street Zen upgraded shares of Apnimed to a “hold” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $50.33.

Apnimed Stock Performance

APMD opened at $28.72 on Tuesday. Apnimed has a 1-year low of $16.12 and a 1-year high of $35.29.

Insider Buying and Selling

In other Apnimed news, major shareholder Morningside Venture Investment acquired 312,500 shares of Apnimed stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the purchase, the insider owned 7,152,713 shares in the company, valued at $114,443,408. The trade was a 4.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

About Apnimed

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.